SMA Drug Pipeline: RNA Splicing & Gene Therapy — PatSnap Eureka
Spinal Muscular Atrophy: RNA Splicing Modulators & Gene Therapy Pipeline
SMA remains a leading genetic cause of infant mortality. PatSnap Eureka maps the complete patent landscape — from ISS-N1 ASOs and AAV9 gene replacement to base editing and combination regimens — so your R&D team can act on what matters.
SMN1, SMN2, and the Exon 7 Splicing Problem
Spinal muscular atrophy (SMA) is caused by insufficient levels of the Survival Motor Neuron (SMN) protein, arising from homozygous deletion or mutation of the SMN1 gene located on chromosome 5q13. The result is progressive motor neuron degeneration, muscle wasting, and paralysis — and SMA remains a leading genetic cause of infant mortality. As documented by the NIH National Institute of Neurological Disorders and Stroke, early intervention is critical to outcomes.
The SMN locus contains two inverted gene copies — SMN1 and SMN2 — and most SMA patients retain at least one SMN2 copy. A single nucleotide difference (C840T in exon 7) disrupts an exonic splicing enhancer, causing approximately 85–90% of SMN2 transcripts to skip exon 7 and produce a truncated, unstable protein (SMNΔ7). This molecular distinction is the dominant therapeutic target across all modalities in the dataset.
Multiple patents specifically identify the intronic splicing silencer element ISS-N1 (located in intron 7 of SMN2) as a key negative regulatory element whose blockade promotes exon 7 inclusion. Iowa State University Research Foundation further delineates deep intronic targets within intron 7, including a 6-nucleotide sequence responsible for long-range steric inhibitory interactions — a novel target distinct from ISS-N1 enabling smaller 5-mer and 8-mer oligonucleotide tools. The PatSnap life sciences intelligence platform aggregates these filings for rapid landscape analysis.
Secondary molecular targets identified in the dataset include BMP and FGF signaling cascades, translational regulators (pumilio, eIF-4E), myostatin (GDF-8), complement pathway components, SMN2 promoter regions, microRNAs (miR-23a, miR-181a-5p, miR-34), 15-hydroxyprostaglandin dehydrogenase (15-PGDH), and ALK4:ActRIIB pathway components. These represent alternative or adjunct targets aimed at neuroprotection or muscle preservation rather than primary SMN correction.
Six Mechanistic Pillars in the SMA Patent Landscape
From steric ASO blockade of ISS-N1 to base editing of SMN2 exon 7, the dataset reveals six distinct mechanistic approaches — each with unique IP assignees, development stages, and combination potential.
Antisense Oligonucleotides (ASOs) Targeting SMN2 Splicing
ASO-based splicing modulation is the most heavily represented modality in this dataset. The mechanistic basis is steric blockade of splicing silencer elements — primarily ISS-N1 in SMN2 intron 7 — to redirect the spliceosome toward exon 7 inclusion. Multiple distinct chemical scaffolds are represented: morpholino oligonucleotides (Sarepta), tricyclic DNA ASOs (University of Bern), peptide-conjugated ASOs (University of Alberta DG9), spherical nucleic acid constructs (Exicure), and short 8-mer/5-mer oligoribonucleotides (Iowa State). Nusinersen (Spinraza) is referenced as an established approved ASO therapy across multiple filings.
Nusinersen referenced as approved benchmarkSmall Molecule SMN2 Splicing Modulators
Orally bioavailable small molecules selectively enhance SMN2 exon 7 inclusion, representing an alternative to intrathecally administered ASOs. F. Hoffmann-La Roche AG holds a substantial portfolio. The dataset references RG7800, SMN-C2, and SMN-C3 as Roche/PTC Therapeutics compounds that increase SMN protein levels in both brain and muscle in SMA mouse models. Phase 2 clinical trial references (NCT02913482, NCT03032172, NCT02908685, NCT02268552) appear in the Scholar Rock filing for these oral programs. Reborna Biosciences holds active patents on proprietary heterocyclic formula (I) compounds. HDAC inhibitors (valproic acid, trichostatin A) are noted as increasing SMN2 transcription but risk global dysregulation at therapeutic doses.
Phase 2 trial references: RG7800, SMN-C2, SMN-C3AAV-Mediated SMN1 Gene Replacement Therapy
Recombinant adeno-associated virus (rAAV) — specifically self-complementary AAV9 (scAAV9) vectors encoding full-length SMN1 — is the second major platform. Genzyme Corporation (Sanofi) holds an extensive patent family across multiple jurisdictions (US, WO, CA, AU, IN, MX) covering intrathecal and cisterna magna delivery of scAAV9-SMN in pediatric human subjects. University of Massachusetts filings (2022–2024) describe next-generation rAAV vectors with reduced toxicity and increased transgene expression relative to prior scAAV9-SMN constructs. Risdiplam and Zolgensma (scAAV9-SMN) are referenced alongside nusinersen as breakthrough approved modalities. Biocad files an AAV9 vector co-encoding SMN1 and miR-23a for synergistic muscle protection.
Genzyme: active filings across 6+ jurisdictions through 2024Gene Editing (Base Editing / CRISPR) of SMN2
Two significant filings represent an emerging gene editing approach: converting the SMN2 pseudogene into a functional SMN1-like gene by correcting the C840T mutation in exon 7, or inactivating degron sequences that destabilize SMN2 protein. Harvard College's 2025 EP patent (currently active) describes base editors and cognate guide RNAs to install C840T edits in SMN2 exon 7, or to remove degron activity in regions encoded by exon 6 or the EMLA-tail of exon 8 (SEQ ID NO: 466). The Broad Institute (2024 WO) provides complementary base editor and nuclease strategies. Both filings represent preclinical-stage IP. If successful in vivo, base editing could offer a one-time curative intervention without the SMN1 copy-number limitation of AAV-delivered gene replacement.
Harvard EP active 2025 · Broad Institute WO 2024RNA Activation (saRNA) of SMN2 Promoter
Ractigen Therapeutics files across multiple jurisdictions on small activating RNA (saRNA) molecules — double-stranded oligonucleotides of 16–35 nucleotides targeting the SMN2 gene promoter region — that upregulate SMN2 transcription rather than modulating splicing. This represents a mechanistically distinct approach to boosting SMN protein output, orthogonal to splicing modulation, and could theoretically be combined with splicing modulators for additive SMN protein output. Filings span EP, CA, and MX jurisdictions.
Ractigen: EP, CA, MX filings · 16–35 nt saRNA constructsMuscle-Targeted & Neuroprotective Adjunct Approaches
Multiple retrieved results address SMN-independent targets relevant to muscle pathology. Scholar Rock holds active patent families on myostatin pathway inhibition including apitegromab — with the filing stating apitegromab administration leads to improvements in motor function and/or quality of life in SMA subjects. Acceleron Pharma targets ALK4:ActRIIB antagonism for SMA muscle complications. Annexon proposes complement inhibitors as synapse-protective adjuncts, noting neurotoxicity signals in animal models of nusinersen. Epirium Bio's 2025 WO filing — the most recent in the dataset — proposes a 15-PGDH inhibitor combined with any SMN-augmenting agent. Sorbonne Université files on phytoecdysone combinations with SMN-restoring agents.
Epirium Bio 2025: most recent filing in datasetSMA Innovation Signals: Filing Trends & Modality Breakdown
Key quantitative signals from the PatSnap Eureka SMA patent and literature dataset, illustrating the trajectory of combination therapy filings and the distribution of mechanistic approaches.
SMA Combination Therapy Patent Filing Activity by Year
Filing volume for combination SMA approaches has accelerated sharply from 2019 onward, reflecting strategic recognition that single-modality SMN correction leaves residual disease burden.
SMA Patent Activity by Therapeutic Modality
ASO splicing modulators dominate the dataset, followed by AAV gene therapy and small molecules. Gene editing (base editing) represents an emerging but rapidly growing share.
Emerging Combination Regimens & Strategic IP Signals
The most active recent filings are combination claims — reflecting that single-modality SMN correction may leave residual disease burden, particularly in the muscle compartment.
ASO + Gene Therapy (SMN1 vector)
Biogen MA Inc. files multiple patents (WO 2020, US 2021, US 2022) pairing intrathecal ASO (nusinersen-like) with systemic scAAV9-SMN1 delivery, with extended claims to include small molecule SMN2 modulators as a third component. This represents the most commercially aggressive combination patent position in the dataset.
SMN Corrector + Myostatin Inhibitor
Scholar Rock's active patent portfolio (EP, MY, IL; 2019–2023) explicitly claims the combination of myostatin inhibitors with neuronal correctors (ASO or gene therapy) to address both neural and muscle compartments of SMA. The filing states apitegromab administration leads to improvements in motor function and/or quality of life in SMA subjects.
Gene Therapy + microRNA (SMN1 + miR-23a)
Biocad's AAV9 vector co-encoding SMN1 and miR-23a signals an emerging direction integrating microRNA-mediated muscle protection alongside gene replacement, distinct from two-drug combination approaches and filing across IL jurisdiction in 2023.
ASO + Subclinical HDAC Inhibitor
Cold Spring Harbor Laboratory and CONICET filings (2021–2023) propose that subclinical doses of valproic acid or trichostatin A combined with intron 7-targeting ASO achieve synergistic exon 7 inclusion while avoiding the toxicity of HDAC inhibitors at therapeutic doses.
Key Patent Assignees Across the SMA Pipeline
Activity in this dataset is predominantly patent-driven, with commercial and academic institutions filing across multiple jurisdictions. The table below maps key organisational clusters to their modality and IP status.
| Assignee | Modality / Approach | Jurisdictions | Status Signal |
|---|---|---|---|
| Genzyme Corporation (Sanofi) | scAAV9-SMN1 gene replacement | US, WO, CA, AU, IN, MX | Active through 2024 |
| F. Hoffmann-La Roche AG | Small molecule SMN2 splicing modulators | IL (multiple) | Active |
| Biogen MA Inc. | ASO + gene therapy combination | US, WO | Active |
| University of Massachusetts | ISS-N1 ASO IP + next-gen rAAV vectors | US, WO, AU, CA | Active 2022–2024 |
| Harvard College / Broad Institute | Base editing of SMN2 exon 7 | EP, WO | EP Active 2025 |
| Scholar Rock, Inc. | Myostatin inhibitor + neuronal corrector | EP, MY, IL | Active 2019–2023 |
| Sarepta Therapeutics, Inc. | Morpholino ASO for exon 7 inclusion | ES | 2019 |
| Reborna Biosciences, Inc. | Proprietary heterocyclic SMN-enhancing compounds | NZ, MY, IL | Active 2021–2024 |
| Ractigen Therapeutics | saRNA SMN2 promoter activation | EP, CA, MX | Active |
| Epirium Bio Inc. | 15-PGDH inhibitor + SMN-augmenting agent | WO | 2025 — Newest |
Need freedom-to-operate analysis for SMA combinations?
PatSnap Eureka surfaces overlapping claims across foundational ASO and gene therapy patents in seconds.
What the SMA Patent Landscape Signals for R&D Strategy
IP convergence on combination therapy: The most active and recent patent filings in this dataset (Biogen, Scholar Rock, Epirium Bio, Cold Spring Harbor/CONICET) are combination claims, reflecting a strategic recognition that single-modality SMN correction may leave residual disease burden — particularly in the muscle compartment — that requires adjunctive targeting. IP strategists should monitor the freedom-to-operate landscape as combination claims overlap with foundational ASO and gene therapy patents. PatSnap's IP analytics platform enables rapid landscape scanning across all relevant claim families.
Gene editing as next-wave platform: Harvard College and the Broad Institute have filed active base editing IP for SMN2 correction as recently as 2024–2025. If base editing achieves durable SMN2-to-SMN1-like correction in vivo, this could disrupt the recurring-dosing economics of ASOs and the single-dose pricing model of AAV gene therapy. Early-stage IP landscape analysis is warranted for developers considering base editing for SMA. Regulatory guidance from the FDA on gene editing products continues to evolve in parallel.
Next-generation AAV vectors under development: University of Massachusetts' 2022–2024 filings on rAAV vectors with reduced toxicity and improved transgene expression relative to prior scAAV9-SMN constructs signal active R&D iteration on the gene therapy platform. This positions UMass as a source of IP that could differentiate future gene therapy products from the first-generation approved vector. PatSnap customers in gene therapy have used similar landscape analyses to identify licensing opportunities early.
Delivery innovation as IP differentiator: The SNA-ASO platform (Exicure/Bart Anderson) and peptide-conjugated ASOs (University of Alberta DG9) represent delivery-focused IP that could extend the reach of established SMN2-targeting oligonucleotides — particularly for CNS penetration and systemic muscle delivery — without requiring novel sequence claims. Drug developers and licensors should evaluate delivery platform IP as a distinct value layer in SMA therapeutics. Developers building on open platforms may benefit from PatSnap's open API for programmatic IP monitoring.
SMA Drug Pipeline — Key Questions Answered
SMA is caused by insufficient levels of the Survival Motor Neuron (SMN) protein, arising from homozygous deletion or mutation of the SMN1 gene located on chromosome 5q13, resulting in progressive motor neuron degeneration, muscle wasting, and paralysis.
RNA splicing modulators work via steric blockade of splicing silencer elements — primarily ISS-N1 in SMN2 intron 7 — to redirect the spliceosome toward exon 7 inclusion, increasing production of full-length, functional SMN protein from the paralogous SMN2 gene.
ASO-based splicing modulation requires intrathecal administration and works via steric blockade of splicing silencer elements. Small molecule SMN2 splicing modulators such as RG7800, SMN-C2, and SMN-C3 are orally bioavailable and selectively enhance SMN2 exon 7 inclusion, representing an alternative to intrathecally administered ASOs.
Self-complementary AAV9 (scAAV9) vectors encoding full-length SMN1 are the primary gene therapy platform for SMA. Genzyme Corporation holds an extensive patent family covering intrathecal and cisterna magna delivery of scAAV9-SMN in pediatric human subjects. University of Massachusetts filings describe next-generation rAAV vectors with reduced toxicity and increased transgene expression relative to prior scAAV9-SMN constructs.
Base editing for SMA involves converting the SMN2 pseudogene into a functional SMN1-like gene by correcting the C840T mutation in exon 7, or by inactivating degron sequences that destabilize SMN2 protein. Harvard College's 2025 EP patent describes base editors and cognate guide RNAs to install C840T edits in SMN2 exon 7, or to remove degron activity in regions encoded by exon 6 or the EMLA-tail of exon 8.
The most active and recent patent filings in the SMA dataset are combination claims, reflecting a strategic recognition that single-modality SMN correction may leave residual disease burden — particularly in the muscle compartment — that requires adjunctive targeting. Key combinations include ASO plus gene therapy, SMN corrector plus myostatin inhibitor, and ASO plus HDAC inhibitor at subclinical dose.
Still have questions about the SMA patent landscape? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About SMAAccelerate Your SMA R&D with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map drug pipelines, identify white space, and monitor competitor filings — across every SMA modality and jurisdiction.
References
- Induced exon inclusion in spinal muscular atrophy — Sarepta Therapeutics, Inc., 2019, ES [Patent]
- SMA treatment via targeting of SMN2 splice site inhibitory sequences — University of Massachusetts, 2010, US [Patent]
- SMA treatment via targeting of SMN2 splice site inhibitory sequences — University of Massachusetts, 2024, US [Patent]
- A deep intronic target for splicing correction on SMA gene — Iowa State University Research Foundation, 2014, WO [Patent]
- Deep intronic target for splicing correction on SMA gene — Iowa State University Research Foundation, 2018, US [Patent]
- SMA treatment via targeting SMN2 catalytic core — Iowa State University Research Foundation, 2015, US [Patent]
- Treatment of neurological diseases using modulators of SMN2 gene transcripts — Hinckley, Sandra, 2023, WO [Patent]
- Compositions and Methods for Treating SMA — Genzyme Corporation, 2024, US [Patent]
- Compositions and methods for treating SMA — Genzyme Corporation, 2015, AU [Patent]
- Compositions and methods for treating SMA — Genzyme Corporation, 2014, WO [Patent]
- Gene therapy for spinal muscular atrophy — University of Massachusetts, 2023, WO [Patent]
- Gene therapy for spinal muscular atrophy — University of Massachusetts, 2023, CA [Patent]
- Gene therapy for spinal muscular atrophy — University of Massachusetts, 2024, AU [Patent]
- Gene editing methods for treating SMA — President and Fellows of Harvard College, 2025, EP [Patent]
- Compounds for treating spinal muscular atrophy — F. Hoffmann-La Roche AG, 2019, IL [Patent]
- Prophylactic or therapeutic agent for SMA — Reborna Biosciences, Inc., 2024, NZ [Patent]
- Compositions for treatment of SMA — Cold Spring Harbor Laboratory, 2023, US [Patent]
- Synergistic effect of SMN1 and mir-23a in treating SMA — Joint Stock Company "Biocad", 2023, IL [Patent]
- Nucleic acid constructs for treating SMA — Hangzhou Exegenesis Bio Ltd., 2023, IL [Patent]
- Liposomal SNA constructs for SMN inhibitors — Anderson, Bart, 2019, WO [Patent]
- NIH National Institute of Neurological Disorders and Stroke — Spinal Muscular Atrophy information
- U.S. Food and Drug Administration — Gene therapy regulatory guidance
- World Health Organization — Rare disease and genetic disorder resources
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Patent data represents a snapshot of records retrieved across targeted searches and should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.